No Irish bar for Teva on Mylan glatiramer
Executive Summary
Teva has been refused by Ireland’s High Court an injunction to stop Mylan producing its US rival to Copaxone (glatiramer acetate) 40mg/ml at a local facility in Inverin, County Galway. The Israeli firm had claimed that Mylan’s production of the generic version of the multiple-sclerosis brand infringed the Irish counterpart of European patent EP2,949,335, titled ‘low frequency glatiramer acetate therapy’.